EGFR and lung cancer: Although recent work has identified drug-susceptible driver mutations in lung cancer, including ALK (anaplastic lymphoma kinase) translocations and EGFR (epidermal growth factor receptor) mutations, LADC patients harboring SWI/SNF complex mutations often lack these driver gene mutations (12,13), a discrepancy that underscores the importance of developing new treatment strategies.